Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.18% | -2.36% | -10.47% | -2.44% | 20.49% |
| Total Depreciation and Amortization | -0.78% | -1.92% | -1.81% | -0.82% | -1.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.17% | -10.19% | 13.76% | -34.34% | 68.66% |
| Change in Net Operating Assets | 190.54% | 53.27% | -10.81% | 28.97% | -248.33% |
| Cash from Operations | 7.85% | 10.07% | -10.79% | -0.01% | 6.97% |
| Capital Expenditure | -400.00% | 70.59% | -14.86% | 41.73% | 55.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 730.04% | -87.64% | 18.27% | 43.18% | -23.40% |
| Cash from Investing | 732.11% | -87.68% | 18.28% | 43.47% | -22.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.07% | -42.11% | 89.84% | 32.00% | -257.14% |
| Cash from Financing | 348.15% | -136.49% | 139.57% | -12.65% | -115.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.70% | -293.57% | 50.16% | 352.58% | -229.63% |